Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kringle PharmaTSE:4884 48 Net-Net Working Capital is 円90.94 as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 48/100 and a GF Value™ of 円476.90 (Fairly Valued). The stock has 5 warning signs investors should review. Among 838 Biotechnology companies, Kringle Pharma ranks better than 65.63% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Kringle Pharma's Net-Net Working Capital for the quarter that ended in Mar. 2026 was 円90.94.
The industry rank for Kringle Pharma's Net-Net Working Capital or its related term are showing as below:
TSE:4884's Price-to-Net-Net-Working-Capital is ranked better than 65.63% of 838
companies
in the Biotechnology industry
Industry Median: 5.315
vs TSE:4884: 3.41
Kringle Pharma (TSE:4884) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Kringle Pharma Net-Net Working Capital Related Terms
Kringle Pharma Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, MRNA: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Kringle Pharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of 円90.94 mean?
Kringle Pharma (TSE:4884) has a Net-Net Working Capital of 円90.94 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Kringle Pharma According to the industry distribution chart, Kringle Pharma ranks #288 out of 838 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Kringle Pharma's Net-Net Working Capital too high?
Kringle Pharma's current Net-Net Working Capital is 円90.94. Based on the distribution chart, Kringle Pharma ranks #288 out of 838 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kringle Pharma has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #288 out of 838 companies for Net-Net Working Capital. This puts Kringle Pharma in the upper half of its industry. The industry median Net-Net Working Capital is 5.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.32, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Kringle Pharma For the Biotechnology industry, the median Net-Net Working Capital is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kringle Pharma's current Net-Net Working Capital is 円90.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Fairly Valued. The stock's GF Value™ is 円476.90, compared to a current price of 円439.00 — trading 7.9% below its estimated fair value. The current Net-Net Working Capital is 円90.94. Kringle Pharma's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Net-Net Working Capital is 円90.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円439.00 is trading 7.9% below its estimated GF Value™ of 円476.90.
GuruFocus considers Kringle Pharma to be Fairly Valued.
Key valuation signals for TSE:4884:
Net-Net Working Capital: 円90.94
GF Value™: 円476.90 vs. price of 円439.00 (7.9% below fair value)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
48GF Score
Get the complete analysis for TSE:4884
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
